Compare DexCom, Inc. (DXCM) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Redwire Corporation — how do they compare? DexCom, Inc. trades at $84.88 (market cap $31.86B), while Redwire Corporation trades at $9.54 (market cap $2.44B). The key difference: DexCom, Inc. is far larger — about 13.1× Redwire Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Redwire Corporation for 18 Days on average.
| DXCM | RDW | |
|---|---|---|
Market Cap | $31.86B | $2.44B |
Volume | 3,607,070 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $92.34 | $25.90 |
52-Week Low | $54.84 | $5.06 |
Typical Hold Time | 62 Days | 18 Days |
Enterprise Value | $31.32B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Redwire Corporation (RDW) trades at $9.53, down 6.93% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, while revenue grew to $335.38M in 2025. Recent positive developments include a $981M Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data centers.
Despite strong analyst support (80% buy ratings) and a $14.88 price target representing 56% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents a high-risk opportunity for investors betting on space infrastructure growth, but requires careful monitoring of profitability improvements and execution on contract wins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
